https://mazetx.com/bridgebio-pharma-and-maze-therapeutics-establish-joint-venture-to-advance-precision-medicine-to-treat-cardiovascular-disease/ 2021-03-11T15:48:37+00:00 https://mazetx.com/maze-therapeutics-and-alloy-therapeutics-form-broadwing-bio-to-develop-antibody-therapies-for-genetically-validated-targets-in-ophthalmic-diseases/ 2021-03-11T15:49:03+00:00 https://mazetx.com/maze-therapeutics-expands-experienced-management-team-with-appointment-of-sarah-noonberg-m-d-ph-d-as-chief-medical-officer/ 2021-03-11T15:49:32+00:00 https://mazetx.com/maze-therapeutics-appoints-city-hill-founder-jonathan-lim-m-d-to-its-board-of-directors/ 2021-03-11T16:04:42+00:00 https://mazetx.com/fiercebiotech-names-maze-therapeutics-as-one-of-its-fierce-15-biotech-companies-of-2019/ 2021-03-11T16:05:04+00:00 https://mazetx.com/maze-therapeutics-appoints-drug-development-expert-richard-scheller-ph-d-to-its-board-of-directors/ 2021-03-11T16:05:29+00:00 https://mazetx.com/maze-therapeutics-appoints-jason-coloma-as-chief-executive-officer-and-expands-leadership-team/ 2021-03-11T16:05:49+00:00 https://mazetx.com/maze-therapeutics-launches-with-191-million-to-focus-on-translating-genetic-insights-into-new-medicines/ 2021-03-11T16:06:01+00:00 https://mazetx.com/maze-therapeutics-appoints-atul-dandekar-as-chief-strategy-officer-and-expands-board-of-directors/ 2021-03-23T14:50:19+00:00 https://mazetx.com/maze-therapeutics-reveals-its-initial-three-lead-programs-targeting-underlying-genetic-drivers-of-life-threatening-diseases/ 2021-03-23T15:07:37+00:00 https://mazetx.com/maze-therapeutics-to-present-at-the-40th-annual-j-p-morgan-healthcare-conference/ 2022-01-07T21:00:43+00:00 https://mazetx.com/maze-therapeutics-to-present-preclinical-data-highlighting-mze001-as-a-potential-treatment-for-pompe-disease-at-2022-world-symposium/ 2022-02-10T23:14:27+00:00 https://mazetx.com/maze-therapeutics-announces-190-million-financing-to-support-the-advancement-of-nine-precision-medicine-programs-and-compass-platform-for-genetically-defined-diseases/ 2022-02-10T23:16:01+00:00 https://mazetx.com/maze-therapeutics-presents-new-preclinical-data-supporting-advancement-of-mze001-as-a-potential-treatment-for-pompe-disease/ 2022-02-10T23:20:55+00:00 https://mazetx.com/maze-therapeutics-announces-phase-1-trial-initiation-evaluating-mze001-as-a-potential-oral-treatment-for-pompe-disease/ 2022-02-17T18:57:35+00:00 https://mazetx.com/maze-therapeutics-announces-publication-in-nature-describing-a-novel-mechanism-linking-well-established-genetic-drivers-of-als-and-ftd-2/ 2022-06-29T21:36:50+00:00 https://mazetx.com/maze-therapeutics-announces-fda-orphan-drug-designation-granted-to-mze001-for-the-treatment-of-pompe-diseaselifesci-2nd-annual-genetic-medicines-symposium-2022/ 2022-09-22T14:22:00+00:00 https://mazetx.com/maze-therapeutics-appoints-sekar-kathiresan-m-d-to-its-board-of-directors/ 2022-11-04T14:38:10+00:00 https://mazetx.com/maze-therapeutics-appoints-harold-bernstein-m-d-ph-d-as-president-research-and-development-and-chief-medical-officer/ 2023-01-03T15:45:12+00:00 https://mazetx.com/maze-therapeutics-presents-preclinical-data-highlighting-potential-of-apol1-inhibitor-program-as-a-treatment-for-chronic-kidney-disease/ 2023-02-27T14:27:39+00:00 https://mazetx.com/maze-therapeutics-announces-completion-of-phase-1-first-in-human-trial-evaluating-mze001-as-a-potential-oral-treatment-for-pompe-disease/ 2023-03-22T15:59:28+00:00 https://mazetx.com/maze-therapeutics-announces-new-clinical-data-supporting-mze001-as-a-potential-treatment-for-pompe-disease/ 2023-03-22T16:35:33+00:00 https://mazetx.com/biotech-startup-maze-therapeutics-strikes-750-million-deal-with-sanofi/ 2023-05-01T12:54:36+00:00 https://mazetx.com/sanofi-bets-750m-to-enter-glycogen-lined-maze-deal-with-lead-asset-waiting-in-the-middle/ 2023-05-01T12:56:28+00:00 https://mazetx.com/biotech-startup-maze-therapeutics-strikes-750-million-deal-with-sanofi-2/ 2023-05-01T13:00:58+00:00 https://mazetx.com/maze-therapeutics-presents-preclinical-data-highlighting-potential-of-apol1-inhibitor-program-as-a-treatment-for-chronic-kidney-disease-2/ 2023-06-29T15:36:15+00:00 https://mazetx.com/live-webcast-maze-therapeutics-to-participate-in-the-2023-jefferies-healthcare-conference/ 2023-07-18T12:57:53+00:00 https://mazetx.com/maze-therapeutics-announces-new-clinical-data-supporting-mze001-as-a-potential-treatment-for-pompe-disease-2/ 2023-07-18T14:00:02+00:00 https://mazetx.com/the-endpoints-11-the-biotech-startups-making-the-biggest-bets-with-the-most-exciting-science-in-2023/ 2023-09-27T14:31:45+00:00 https://mazetx.com/wp-content/uploads/2023/09/E11_23_fi.jpg https://mazetx.com/maze-therapeutics-announces-publication-of-research-demonstrating-newly-identified-variant-for-apol1-kidney-disease-is-associated-with-reduced-risk-of-apol1-kidney-disease/ 2023-11-03T19:34:34+00:00 https://mazetx.com/maze-therapeutics-to-participate-in-the-2023-cantor-fitzgerald-global-healthcare-conference/ 2023-11-03T19:34:55+00:00 https://mazetx.com/maze-therapeutics-highlights-new-preclinical-data-supporting-advancement-of-apol1-inhibitor-candidate-toward-clinical-evaluation-for-apol1-kidney-disease/ 2024-03-15T14:32:49+00:00 https://mazetx.com/maze-therapeutics-to-present-new-data-for-apol1-kidney-disease-in-proprietary-chronic-preclinical-model-demonstrating-reversal-of-albuminuria/ 2024-03-15T14:33:11+00:00 https://mazetx.com/maze-therapeutics-highlights-new-preclinical-data-supporting-advancement-of-apol1-inhibitor-candidate-toward-clinical-evaluation-for-apol1-kidney-disease-2/ 2024-03-15T14:34:30+00:00 https://mazetx.com/maze-therapeutics-highlights-new-preclinical-data-supporting-advancement-of-apol1-inhibitor-candidate-toward-clinical-evaluation-for-apol1-kidney-disease-2-2-2/ 2024-04-25T12:48:28+00:00 https://mazetx.com/maze-therapeutics-highlights-new-preclinical-data-supporting-advancement-of-apol1-inhibitor-candidate-toward-clinical-evaluation-for-apol1-kidney-disease-2-2/ 2024-04-25T14:48:30+00:00 https://mazetx.com/wp-content-uploads-2024-01-maze-tx-jpm-podium-presentation-final-jan-7-2024-pdf/ 2024-05-01T14:15:17+00:00 https://mazetx.com/sanofis-next-chapter-in-pompe-150m-for-maze-pact-as-the-biotech-gears-up-in-ckd/ 2024-05-03T10:44:34+00:00 https://mazetx.com/sanofi-stock-rises-on-licensing-deal-with-maze-for-potential-pompe-disease-drug/ 2024-05-03T10:45:33+00:00 https://mazetx.com/early-clinical-data-drove-sanofis-decision-to-license-mazes-oral-pompe-therapy/ 2024-05-03T10:46:09+00:00 https://mazetx.com/sanofi-pumps-up-its-pompe-portfolio-with-maze-deal/ 2024-05-03T10:46:28+00:00 https://mazetx.com/sanofi-finds-way-to-maze-therapeutics-to-get-its-next-pompe-disease-drug/ 2024-05-03T10:47:31+00:00 https://mazetx.com/exclusive-maze-unveils-their-191m-pipeline-taking-on-vertex-and-two-long-sought-conditions-2/ 2024-05-03T10:51:10+00:00 https://mazetx.com/maze-therapeutics-announces-publication-in-nature-describing-a-novel-mechanism-linking-well-established-genetic-drivers-of-als-and-ftd/ 2024-05-03T10:53:55+00:00 https://mazetx.com/exclusive-maze-unveils-their-191m-pipeline-taking-on-vertex-and-two-long-sought-conditions/ 2024-05-03T10:54:07+00:00 https://mazetx.com/maze-allies-with-bridgebio-and-alloy-to-create-2-biotechs/ 2024-05-03T10:56:30+00:00 https://mazetx.com/third-rock-and-arch-backed-genetics-startup-launches-with-nearly-200-million/ 2024-05-03T10:56:46+00:00 https://mazetx.com/with-191m-haul-maze-therapeutics-takes-aim-at-genetic-diseases/ 2024-05-03T10:57:31+00:00 https://mazetx.com/the-secret-to-a-new-drug-could-be-hiding-in-your-genes/ 2024-05-03T10:57:49+00:00 https://mazetx.com/sanofi-strikes-a-150m-deal-for-mazes-pompe-disease-drug/ 2024-05-03T14:29:30+00:00 https://mazetx.com/after-ftc-stalled-sanofi-deal-shionogi-secures-mazes-pompe-disease-drug-for-150m/ 2024-05-10T12:39:59+00:00 https://mazetx.com/after-its-last-deal-fell-through-maze-therapeutics-finds-new-partner-for-rare-disease-drug/ 2024-05-10T12:42:21+00:00 https://mazetx.com/after-ftc-scrutiny-of-sanofi-deal-maze-finds-a-new-pompe-partner-in-shionogi/ 2024-05-10T12:43:54+00:00 https://mazetx.com/maze-therapeutics-highlights-new-preclinical-data-supporting-advancement-of-apol1-inhibitor-candidate-toward-clinical-evaluation-for-apol1-kidney-disease-2-2-2-2/ 2024-05-10T14:00:13+00:00 https://mazetx.com/maze-corporate-presentation-july-2024/ 2024-07-15T15:50:19+00:00 https://mazetx.com/maze-therapeutics-initiates-phase-1-first-in-human-trial-evaluating-mze782-as-a-potential-treatment-for-chronic-kidney-disease/ 2024-10-02T20:38:58+00:00 https://mazetx.com/maze-therapeutics-to-present-new-data-supporting-advancement-of-mze829-and-mze782-clinical-development-at-american-society-of-nephrologys-kidney-week-and-american-society-of-human-genetics-an/ 2024-10-16T17:07:03+00:00 https://mazetx.com/wp-content/uploads/2019/06/shutterstock_43031179_smaller_v2.jpg https://mazetx.com/maze-therapeutics-reports-positive-first-in-human-data-from-phase-1-healthy-volunteer-clinical-trial-evaluating-mze829-as-a-potential-treatment-for-apol1-kidney-disease-akd/ 2024-10-25T13:11:29+00:00 https://mazetx.com/wp-content/uploads/2019/06/shutterstock_43031179_smaller_v2.jpg https://mazetx.com/january-2024-i-maze-therapeutics-2-2-2-2-2/ 2024-12-05T20:28:14+00:00 https://mazetx.com/january-2024-i-maze-therapeutics-2-2-2-2/ 2024-12-05T20:30:07+00:00 https://mazetx.com/after-ftc-scrutiny-of-sanofi-deal-maze-finds-a-new-pompe-partner-in-shionogi-2-2/ 2024-12-09T15:18:56+00:00 https://mazetx.com/after-ftc-scrutiny-of-sanofi-deal-maze-finds-a-new-pompe-partner-in-shionogi-2/ 2024-12-09T15:19:22+00:00 https://mazetx.com/maze-therapeutics-initiates-phase-1-first-in-human-trial-evaluating-mze782-as-a-potential-treatment-for-chronic-kidney-disease-2/ 2025-01-03T15:53:06+00:00 https://mazetx.com/maze-therapeutics-to-participate-in-the-2023-jefferies-healthcare-conference/ 2025-01-04T14:29:35+00:00 https://mazetx.com/october-2024-maze-therapeutics/ 2025-01-04T16:05:33+00:00 https://mazetx.com/october-2024-maze-therapeutics-2/ 2025-01-04T16:06:20+00:00 https://mazetx.com/october-2024-maze-therapeutics-3/ 2025-01-04T16:06:41+00:00 https://mazetx.com/july-2013-external-experts/ 2025-01-04T16:07:58+00:00 https://mazetx.com/aug-2018-maze-founder/ 2025-01-04T16:08:20+00:00 https://mazetx.com/oct-2020-maze-therapeutics/ 2025-01-04T16:08:39+00:00 https://mazetx.com/sept-2021-external-experts/ 2025-01-04T16:09:00+00:00 https://mazetx.com/aug-2016-maze-founder/ 2025-01-04T16:09:53+00:00 https://mazetx.com/dec-2019-external-experts/ 2025-01-04T16:10:23+00:00 https://mazetx.com/jan-2020-maze-founder/ 2025-01-04T16:10:38+00:00 https://mazetx.com/apr-2021-internal-expert/ 2025-01-04T16:10:51+00:00 https://mazetx.com/december-2013-external-experts/ 2025-01-04T16:11:04+00:00 https://mazetx.com/june-2021-external-experts/ 2025-01-04T16:11:22+00:00 https://mazetx.com/feb-2022-maze-therapeutics-3/ 2025-01-04T16:11:44+00:00 https://mazetx.com/feb-2022-maze-therapeutics-2/ 2025-01-04T16:12:42+00:00 https://mazetx.com/feb-2022-maze-therapeutics/ 2025-01-04T16:12:54+00:00 https://mazetx.com/november-2022-maze-therapeutics-2/ 2025-01-04T16:13:07+00:00 https://mazetx.com/november-2022-maze-therapeutics/ 2025-01-04T16:13:19+00:00 https://mazetx.com/february-2023-maze-therapeutics-5/ 2025-01-04T16:13:36+00:00 https://mazetx.com/february-2023-maze-therapeutics-4/ 2025-01-04T16:13:48+00:00 https://mazetx.com/february-2023-maze-therapeutics-3/ 2025-01-04T16:14:00+00:00 https://mazetx.com/march-2023-maze-therapeutics/ 2025-01-04T16:14:12+00:00 https://mazetx.com/october-2023-maze-therapeutics-million-veteran-program-and-vanderbilt-university-medical-center/ 2025-01-04T16:14:23+00:00 https://mazetx.com/november-2023-maze-therapeutics/ 2025-01-04T16:14:38+00:00 https://mazetx.com/july-2022-maze-therapeutics/ 2025-01-04T16:14:46+00:00 https://mazetx.com/feb-2022-nature/ 2025-01-04T16:14:53+00:00 https://mazetx.com/feb-2022-maze-therapeutics-4/ 2025-01-04T16:14:58+00:00 https://mazetx.com/jul-2019-external-experts/ 2025-01-04T16:18:51+00:00 https://mazetx.com/top-life-sciences-startups-to-watch-in-2020/ 2025-01-04T16:31:09+00:00 https://mazetx.com/getasset/f543f3b7-ef0d-4bb0-837d-af1569a6ba4f/ https://mazetx.com/getasset/3ca5bce6-89da-40a9-8e93-ff03d44b30f0/ https://mazetx.com/getasset/9e4523db-d82f-4057-ad44-c17df9c23e51/ https://mazetx.com/getasset/218518a8-704c-4c23-b551-68ecd5fef1c4/ https://mazetx.com/getasset/c2c11423-2d10-4205-a147-fb5de6c47b68/ https://mazetx.com/getasset/4818f166-59da-46ac-b67f-7bd16488ca0f/ https://mazetx.com/getasset/799d72a7-9975-423a-bc58-23e9de031b29/ https://mazetx.com/getasset/a2b87d0c-b523-4f60-b31c-2970fdcb74a1/ https://mazetx.com/getasset/c036238c-50b8-4b10-966d-dc089aad6d5a/ https://mazetx.com/getasset/4f5f7747-81c3-4531-8636-af63693db12e/ https://mazetx.com/getasset/7d0897ec-6356-429f-b640-f0cb98b4bc52/ https://mazetx.com/getasset/79fc6cec-9c49-4aee-97f0-452d6e737730/ https://mazetx.com/getasset/f8e9f92b-558a-4534-9d7b-28edddf46dc1/ https://mazetx.com/getasset/924c9317-0ef0-4f4f-a6ba-96dd23bfe4dc/ https://mazetx.com/getasset/e79e55c6-8be4-40dc-a6d2-fa0641c64e9e/ https://mazetx.com/getasset/745546ef-deb1-416e-954b-05b3ce82f153/ https://mazetx.com/getasset/a1471386-3061-4f89-87ff-39ee5becaf09/ https://mazetx.com/getasset/ee7e6849-63b4-4727-aa5c-8a6b7252d906/ https://mazetx.com/getasset/28634436-2175-44b3-b7c7-a16059f61be4/ https://mazetx.com/getasset/d3b4fb56-e3a6-4854-bc78-e35a220ea967/ https://mazetx.com/getasset/f5de86a4-307c-4baf-89a4-7ee08ccde9cf/ https://mazetx.com/getasset/70f7305b-b806-4a2e-a26f-c545827871a8/ https://mazetx.com/maze-therapeutics-spins-out-two-new-companies-with-alloy-and-bridgebio/ 2025-01-04T16:31:51+00:00 https://mazetx.com/september-2024-maze-therapeutics/ 2025-02-25T19:02:53+00:00 https://mazetx.com/maze-therapeutics-initiates-phase-1-first-in-human-trial-evaluating-mze782-as-a-potential-treatment-for-chronic-kidney-disease-2-2/ 2025-09-11T20:42:24+00:00 https://mazetx.com/maze-therapeutics-initiates-phase-1-first-in-human-trial-evaluating-mze782-as-a-potential-treatment-for-chronic-kidney-disease-2-2-2/ 2025-09-11T20:46:41+00:00 https://mazetx.com/october-2024-i-maze-therapeutics-2-2-2-2-2-2-2/ 2025-10-29T20:41:30+00:00 https://mazetx.com/january-2024-i-maze-therapeutics-2-2-2-2-2-2/ 2025-10-29T20:41:49+00:00 https://mazetx.com/november-2025-i-maze-therapeutics-3/ 2025-11-06T19:05:00+00:00 https://mazetx.com/november-2025-i-maze-therapeutics-2/ 2025-11-06T19:06:00+00:00 https://mazetx.com/november-2025-i-maze-therapeutics/ 2025-11-06T19:37:56+00:00 https://mazetx.com/november-2025-i-maze-therapeutics-4/ 2025-11-07T18:26:04+00:00 https://mazetx.com/november-2025-i-maze-therapeutics-5/ 2025-11-08T18:05:00+00:00 https://mazetx.com/march-2026-maze-therapeutics-and-certara-inc/ 2026-06-06T15:46:34+00:00 https://mazetx.com/april-2026-maze-therapeutics/ 2026-06-06T15:48:54+00:00 https://mazetx.com/maze-therapeutics-announces-positive-topline-data-from-phase-2-horizon-trial-of-mze829-demonstrating-the-first-clinical-proof-of-concept-in-patients-with-broad-apol1-mediated-kidney-disease/ 2026-08-13T21:00:51+00:00 https://mazetx.com/maze-therapeutics-to-participate-in-the-td-cowen-46th-annual-health-care-conference/ 2026-08-13T21:01:00+00:00 https://mazetx.com/maze-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent-highlights/ 2026-08-13T21:01:03+00:00